Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flovent Diskus Would Be Useful Option With Advair Diskus - FDA Cmte.

Executive Summary

Glaxo Wellcome's Flovent Diskus would be a useful option for titration in conjunction with the Advair Diskus, FDA's Pulmonary-Allergy Drugs Advisory Committee suggested at its Nov. 23 meeting.

You may also be interested in...



Glaxo Flovent Diskus

Fluticasone inhalational powder for Diskus delivery device will not be marketed until 2001, the company said following Sept. 29 approval of the product for maintenance of treatment of asthma as prophylactic therapy for patients four and above. The product is also indicated for patients requiring oral corticosteroid therapy for asthma. Fluticasone is currently marketed in a metered dose inhaler and in a Rotadisk dry powder inhaler. The Flovent Diskus NDA was submitted in March 1998 and has been "approvable" since March 31, 1999 (1"The Pink Sheet" Dec. 6, 1999, p. 8)

Glaxo Flovent Diskus

Fluticasone inhalational powder for Diskus delivery device will not be marketed until 2001, the company said following Sept. 29 approval of the product for maintenance of treatment of asthma as prophylactic therapy for patients four and above. The product is also indicated for patients requiring oral corticosteroid therapy for asthma. Fluticasone is currently marketed in a metered dose inhaler and in a Rotadisk dry powder inhaler. The Flovent Diskus NDA was submitted in March 1998 and has been "approvable" since March 31, 1999 (1"The Pink Sheet" Dec. 6, 1999, p. 8)

Glaxo Wellcome Advair Compliance To Be Studied Following Approval

Glaxo Wellcome plans to look for improved patient compliance with Advair Diskus compared to other asthma treatments in post-marketing studies.

Related Content

UsernamePublicRestriction

Register

PS035258

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel